DiaMedica Therapeutics (DMAC) executive compensation, 2026 proxy

Rick Pauls, President and Chief Executive Officer, was paid $2.7M in 2025, up 76% from $1.6M the year before.

Filed
April 1, 2026
Annual meeting
May 20, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.7M+76% vs prior year
Prior say-on-pay support
94%of votes cast
CEO Total Compensation
$2,727,350For fiscal 2025
Prior Year CEO Total
$1,550,985For fiscal 2024
Say-on-Pay Support
94%At last year meeting

How Pauls was paid

$2.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary24%Option awards61%Non-equity incentive15%All other compensation1%

Named executive officers

ExecutiveTotal
Rick PaulsPresident and Chief Executive Officer$2,727,350
Julie Krop, M.D.Chief Medical Officer$1,707,563
Scott KellenChief Financial Officer and Secretary$1,229,520

What changed and why

  • $2.7MRick Pauls received a total compensation of $2,727,350 in fiscal 2025.
  • Executive compensation programs emphasize pay-for-performance with a significant portion of executive compensation at risk.
  • 94%Approximately 94% of the votes cast were in favor of the say-on-pay proposal last year.
  • Dr. Julie Krop joined the company as Chief Medical Officer effective August 11, 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.